Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications

Margaret McAuley, Noel Mesa-Torres, Aisling McFall, Sarah Morris, Meilan Huang, Angel L. Pey, David Timson

Research output: Contribution to journalArticle

Abstract

Galactokinase catalyses the site- and stereospecificphosphorylation of α-D-galactose. As such it has attracted interest as a biocatalyst for the introduction of phosphate groups into monosaccharides. However, attempts to broaden the substrate range of human galactokinase have generally resulted in substantially reduced activity. The enzyme also has biotechnological potential in enzyme replacement therapy (ERT) for type II galactosemia. The return-to-consensus approach can be used to identify residues which can be altered to increase protein stability and enzyme activity. This approach identified six residues of potential interest in human galactokinase. Some of the single consensus variants increased the catalytic turnover of the enzyme (M60V, D268E, A334S and G373S), but none resulted in improved stability. When all six changes were introduced into the protein (M60V/M180V/D268E/A334S/R366Q/G373S) thermal stability was increased. Molecular dynamics simulations suggested that these changes altered the protein’s conformation at key sites. The number of salt bridges and hydrogen bonds was also increased. Combining the six consensus variations with Y379W (a variant with greater substrate promiscuity) increased the stability of this variant and its turnover towards some substrates. Thus, the six consensus variants can be used to stabilise catalytically interesting variants of human galactokinase and may also be useful if the protein were to be usedin ERT.
Original languageEnglish
Pages (from-to)1088-1095
Number of pages8
JournalChemBioChem
Volume19
Issue number10
DOIs
Publication statusPublished - 26 Apr 2018

Fingerprint

Galactokinase
Human Activities
Enzyme Replacement Therapy
Enzymes
Galactosemias
Protein Conformation
Monosaccharides
Protein Stability
Molecular Dynamics Simulation
Therapeutics
Galactose
Hydrogen
Proteins
Salts
Hot Temperature
Phosphates

Bibliographical note

This is the peer reviewed version of the following article: McAuley, M., Mesa-Torres, N., McFall, A., Morris, S., Huang, M., Pey, A. and Timson, D. J. (2018), Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications. ChemBioChem. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/cbic.201800025/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Cite this

McAuley, Margaret ; Mesa-Torres, Noel ; McFall, Aisling ; Morris, Sarah ; Huang, Meilan ; Pey, Angel L. ; Timson, David. / Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications. In: ChemBioChem. 2018 ; Vol. 19, No. 10. pp. 1088-1095.
@article{178bef57dc78474faa7c5b4e67e4605f,
title = "Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications",
abstract = "Galactokinase catalyses the site- and stereospecificphosphorylation of α-D-galactose. As such it has attracted interest as a biocatalyst for the introduction of phosphate groups into monosaccharides. However, attempts to broaden the substrate range of human galactokinase have generally resulted in substantially reduced activity. The enzyme also has biotechnological potential in enzyme replacement therapy (ERT) for type II galactosemia. The return-to-consensus approach can be used to identify residues which can be altered to increase protein stability and enzyme activity. This approach identified six residues of potential interest in human galactokinase. Some of the single consensus variants increased the catalytic turnover of the enzyme (M60V, D268E, A334S and G373S), but none resulted in improved stability. When all six changes were introduced into the protein (M60V/M180V/D268E/A334S/R366Q/G373S) thermal stability was increased. Molecular dynamics simulations suggested that these changes altered the protein’s conformation at key sites. The number of salt bridges and hydrogen bonds was also increased. Combining the six consensus variations with Y379W (a variant with greater substrate promiscuity) increased the stability of this variant and its turnover towards some substrates. Thus, the six consensus variants can be used to stabilise catalytically interesting variants of human galactokinase and may also be useful if the protein were to be usedin ERT.",
author = "Margaret McAuley and Noel Mesa-Torres and Aisling McFall and Sarah Morris and Meilan Huang and Pey, {Angel L.} and David Timson",
note = "This is the peer reviewed version of the following article: McAuley, M., Mesa-Torres, N., McFall, A., Morris, S., Huang, M., Pey, A. and Timson, D. J. (2018), Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications. ChemBioChem. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/cbic.201800025/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.",
year = "2018",
month = "4",
day = "26",
doi = "10.1002/cbic.201800025",
language = "English",
volume = "19",
pages = "1088--1095",
journal = "ChemBioChem",
issn = "1439-4227",
publisher = "John Wiley & Sons, Ltd",
number = "10",

}

Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications. / McAuley, Margaret; Mesa-Torres, Noel; McFall, Aisling; Morris, Sarah; Huang, Meilan; Pey, Angel L.; Timson, David.

In: ChemBioChem, Vol. 19, No. 10, 26.04.2018, p. 1088-1095.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications

AU - McAuley, Margaret

AU - Mesa-Torres, Noel

AU - McFall, Aisling

AU - Morris, Sarah

AU - Huang, Meilan

AU - Pey, Angel L.

AU - Timson, David

N1 - This is the peer reviewed version of the following article: McAuley, M., Mesa-Torres, N., McFall, A., Morris, S., Huang, M., Pey, A. and Timson, D. J. (2018), Improving the activity and stability of human galactokinase for therapeutic and biotechnological applications. ChemBioChem. , which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/cbic.201800025/full. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

PY - 2018/4/26

Y1 - 2018/4/26

N2 - Galactokinase catalyses the site- and stereospecificphosphorylation of α-D-galactose. As such it has attracted interest as a biocatalyst for the introduction of phosphate groups into monosaccharides. However, attempts to broaden the substrate range of human galactokinase have generally resulted in substantially reduced activity. The enzyme also has biotechnological potential in enzyme replacement therapy (ERT) for type II galactosemia. The return-to-consensus approach can be used to identify residues which can be altered to increase protein stability and enzyme activity. This approach identified six residues of potential interest in human galactokinase. Some of the single consensus variants increased the catalytic turnover of the enzyme (M60V, D268E, A334S and G373S), but none resulted in improved stability. When all six changes were introduced into the protein (M60V/M180V/D268E/A334S/R366Q/G373S) thermal stability was increased. Molecular dynamics simulations suggested that these changes altered the protein’s conformation at key sites. The number of salt bridges and hydrogen bonds was also increased. Combining the six consensus variations with Y379W (a variant with greater substrate promiscuity) increased the stability of this variant and its turnover towards some substrates. Thus, the six consensus variants can be used to stabilise catalytically interesting variants of human galactokinase and may also be useful if the protein were to be usedin ERT.

AB - Galactokinase catalyses the site- and stereospecificphosphorylation of α-D-galactose. As such it has attracted interest as a biocatalyst for the introduction of phosphate groups into monosaccharides. However, attempts to broaden the substrate range of human galactokinase have generally resulted in substantially reduced activity. The enzyme also has biotechnological potential in enzyme replacement therapy (ERT) for type II galactosemia. The return-to-consensus approach can be used to identify residues which can be altered to increase protein stability and enzyme activity. This approach identified six residues of potential interest in human galactokinase. Some of the single consensus variants increased the catalytic turnover of the enzyme (M60V, D268E, A334S and G373S), but none resulted in improved stability. When all six changes were introduced into the protein (M60V/M180V/D268E/A334S/R366Q/G373S) thermal stability was increased. Molecular dynamics simulations suggested that these changes altered the protein’s conformation at key sites. The number of salt bridges and hydrogen bonds was also increased. Combining the six consensus variations with Y379W (a variant with greater substrate promiscuity) increased the stability of this variant and its turnover towards some substrates. Thus, the six consensus variants can be used to stabilise catalytically interesting variants of human galactokinase and may also be useful if the protein were to be usedin ERT.

U2 - 10.1002/cbic.201800025

DO - 10.1002/cbic.201800025

M3 - Article

VL - 19

SP - 1088

EP - 1095

JO - ChemBioChem

JF - ChemBioChem

SN - 1439-4227

IS - 10

ER -